Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Authors: Kieron Dunleavy, Michelle A. Fanale, Jeremy S Abramson, Ariela Noy, Paolo F. Caimi, Stefania Pittaluga, Samir Parekh, Ann S. LaCasce, John W. Hayslip, Deepa Jagadeesh, Sunil Nagpal, Mary Jo Lechowicz, Rakesh Gaur, Andrea N. Lucas, Christopher Melani, Mark Roschewski, Seth M. Steinberg, Elaine S. Jaffe, Brad S. Kahl, Jonathan W. Friedberg, Richard F. Little, Nancy L. Bartlett, Wyndham H. Wilson - The Lancet 2018 cited by 232